Connecting Innovation with Industry and Investment
networking
SPARK Showcase Investor Day
13 August 2026
networking
Apsynora Therapeutics will be joining Spark Showcase as an emerging biotech start-up, presenting our work and connecting with potential partners, investors, and industry leaders. We look forward to sharing our vision, exploring new collaborations, and building relationships to accelerate the development of our innovative therapeutic programmes.
SPARK Showcase Investor Day open_in_new
About Apsynora Therapeutics
Apsynora Therapeutics is a clinical-stage biopharmaceutical company focused on advancing innovative therapeutic solutions. Our lead programme, HT-101, is being developed to reduce or relieve gastrointestinal side effects associated with GLP-1 receptor agonist therapies. By combining clinical development with a science-driven approach, Apsynora Therapeutics aims to improve treatment tolerability and support patients in benefiting from important therapeutic advances.